全文获取类型
收费全文 | 7291篇 |
免费 | 297篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 163篇 |
儿科学 | 130篇 |
妇产科学 | 189篇 |
基础医学 | 879篇 |
口腔科学 | 165篇 |
临床医学 | 497篇 |
内科学 | 1799篇 |
皮肤病学 | 169篇 |
神经病学 | 538篇 |
特种医学 | 147篇 |
外科学 | 1047篇 |
综合类 | 59篇 |
预防医学 | 639篇 |
眼科学 | 181篇 |
药学 | 383篇 |
中国医学 | 31篇 |
肿瘤学 | 605篇 |
出版年
2023年 | 44篇 |
2022年 | 93篇 |
2021年 | 222篇 |
2020年 | 118篇 |
2019年 | 211篇 |
2018年 | 216篇 |
2017年 | 134篇 |
2016年 | 147篇 |
2015年 | 168篇 |
2014年 | 254篇 |
2013年 | 342篇 |
2012年 | 569篇 |
2011年 | 604篇 |
2010年 | 348篇 |
2009年 | 355篇 |
2008年 | 527篇 |
2007年 | 524篇 |
2006年 | 452篇 |
2005年 | 478篇 |
2004年 | 430篇 |
2003年 | 354篇 |
2002年 | 396篇 |
2001年 | 42篇 |
2000年 | 36篇 |
1999年 | 56篇 |
1998年 | 48篇 |
1997年 | 47篇 |
1996年 | 42篇 |
1995年 | 29篇 |
1994年 | 36篇 |
1993年 | 37篇 |
1992年 | 19篇 |
1991年 | 19篇 |
1990年 | 11篇 |
1989年 | 17篇 |
1988年 | 18篇 |
1987年 | 7篇 |
1986年 | 13篇 |
1985年 | 9篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 19篇 |
1980年 | 13篇 |
1979年 | 5篇 |
1978年 | 10篇 |
1976年 | 6篇 |
1975年 | 5篇 |
1974年 | 9篇 |
1973年 | 5篇 |
1971年 | 6篇 |
排序方式: 共有7621条查询结果,搜索用时 15 毫秒
91.
Ignacio Mejía‐Calvo Leonardo E. Lpez‐Jurez Said Vzquez‐Leyva Carlos A. Lpez‐Morales Daniel Montoya‐Escutia Pamela G. Merlos Rivera Jos Enrique Herbert‐Pucheta Luis Gerardo Zepeda‐Vallejo Marco Velasco‐Velzquez Lenin Pavn Sonia M. Prez‐Tapia Emilio Medina‐Rivero 《Journal of Cosmetic Dermatology》2021,20(1):150-158
92.
93.
94.
95.
José-Ignacio Antón Rafael Muñoz de Bustillo Enrique Fernández Macías Jesús Rivera 《The European journal of health economics》2014,15(4):411-431
The aim of this article is to analyze the impact of the decentralization of the public national health system in Spain on citizens’ satisfaction with different dimensions of primary and hospital care. Using micro-data from the Health Barometer 1996–2009 and taking advantage of the exogeneity of the different pace of decentralization across Spain using a difference-in-differences strategy, we find that, in general, decentralization has not improved citizens’ satisfaction with different features of the health services. In our base model, we find that there are even some small negative effects on a subset of variables. Sensitivity analysis confirms that there is no empirical evidence for supporting that decentralization has had a positive impact on citizens’ satisfaction with health care. We outline several possible reasons for this. 相似文献
96.
97.
George Kosmadakis Enrique Da Costa Correia Odette Carceles Frederic Somda Didier Aguilera 《Renal failure》2014,36(4):638-650
Despite the significant technical evolution of the blood purification methods, cardiovascular morbidity and mortality in dialysis patients is still several times higher than that observed in the general population. Vitamins are playing a crucial role in multiple key metabolic pathways. Due to multiple factors, dialysis patients present very often hypo- or hypervitaminosis for a broad range of vitamins. Dialysis in the context of renal replacement therapy is associated with a non-physiological potassium-sparing dietetic regime. Additionally, there is a non-selective intradialytic loss of micro- and macronutrients, deranged intracellular kinetics and gastrointestinal malabsorption due to uratemia. Frequent treatment with antibiotics due to infections associated with the acquired uremia-related immunosuppression may derange the vitamin-producing intestinal microflora. Certain agents prescribed in the context of renal failure or other conditions may reduce the absorption of vitamins from the gastrointestinal tract. These factors may deplete a dialysis patient from vitamins, especially the ones with antioxidant activity that may be associated with cardioprotective properties. In other cases, vitamins metabolized and excreted by the kidneys may be accumulated and exert toxic effects. The scope of this paper is to describe the main issues on vitamin therapy in dialysis patients in view of the ever contradictory opinions and practices. 相似文献
98.
99.
Gonzalo Jr Recondo Enrique Dìaz Canton Màximo de la Vega Martin Greco Gonzalo Sr Recondo Matias E Valsecchi 《World journal of clinical oncology》2014,5(3):440-454
During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2 (HER-2) positive breast cancer. Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food and drug administration (FDA)-approved for the treatment of breast cancer patients with HER-2 over-expressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic updates that succinctly recapitulate what we have learnt over these last years and help us to apply that information in our daily practice. This review will pursue that objective. We will summarize the most relevant and updated information related to the state of the art management of HER-2 positive breast cancer in all the clinical scenarios including the adjuvant, neoadjuvant and metastatic settings. But we will also critically appraise that literature in order to highlight some key clinical concepts that should not be overlooked. Lastly, this review will also point out some of the most promising strategies that are currently being tested and may soon become available. 相似文献
100.